USP1 modulates hepatocellular carcinoma progression via the Hippo/TAZ axis
Dongyi Liu1,2, Quanhui Li1, Yifeng Zang1
1Department of General Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, P. R. China.
Abstract:
Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide. The Hippo signaling pathway has emerged as a significant suppressive pathway for hepatocellular carcinogenesis. The core components of the Hippo pathway constitute a kinase cascade, which inhibits the functional activation of YAP/TAZ. Interestingly, the overactivation of YAP/TAZ is commonly observed in hepatocellular carcinoma, although the inhibitory kinase cascade of the Hippo pathway is still functional. Recent studies have indicated that the ubiquitin‒proteasome system also plays important roles in modulating Hippo signaling activity. Our DUB (deubiquitinase) siRNA screen showed that USP1 is a critical regulator of Hippo signaling activity. Analysis of TCGA data demonstrated that USP1 expression is elevated in HCC and associated with poor survival in HCC patients. RNA sequencing analysis revealed that USP1 depletion affects Hippo signaling activity in HCC cell lines. Mechanistic assays revealed that USP1 is required for Hippo/TAZ axis activity and HCC progression. USP1 interacted with the WW domain of TAZ, which subsequently enhanced TAZ stability by suppressing K11-linked polyubiquitination of TAZ. Our study identifies a novel mechanism linking USP1 and TAZ in regulating the Hippo pathway and one possible therapeutic target for HCC.
Insights
Hepatocellular carcinoma (HCC) progression is linked to USP1, which stabilizes TAZ by preventing its ubiquitylation. USP1 is a potential therapeutic target for HCC, impacting the Hippo signaling pathway.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally.
- The Hippo signaling pathway, including YAP/TAZ, is crucial in suppressing liver cancer.
- The ubiquitin‒proteasome system's role in Hippo signaling is an emerging area of research.
Purpose of the Study:
- To investigate the role of deubiquitinase (DUB) enzymes in regulating Hippo signaling in HCC.
- To identify novel regulators of the Hippo pathway and potential therapeutic targets for HCC.
Main Methods:
- Conducted a deubiquitinase siRNA screen to identify regulators of Hippo signaling.
- Analyzed The Cancer Genome Atlas (TCGA) data for USP1 expression in HCC.
- Performed RNA sequencing and mechanistic assays to elucidate USP1's function.
- Investigated USP1's interaction with TAZ and its effect on TAZ stability.
Main Results:
- USP1 was identified as a critical regulator of Hippo signaling activity.
- Elevated USP1 expression in HCC correlates with poor patient survival.
- USP1 depletion impacts Hippo signaling and HCC cell line activity.
- USP1 enhances TAZ stability by inhibiting its K11-linked polyubiquitination, promoting HCC progression.
Conclusions:
- USP1 plays a key role in regulating the Hippo/TAZ axis in HCC.
- USP1 stabilization of TAZ is a novel mechanism contributing to HCC pathogenesis.
- USP1 represents a potential therapeutic target for hepatocellular carcinoma.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Hedgehog Signaling Pathway
The JAK-STAT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Regulation of Angiogenesis and Blood Supply


